Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | HEXA | P06865 | 1/20 | 0.32 |
| ▸ | HEXB | P07686 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084808 | 0.88 | PDCD1 (0.40) | PDCD1CD274HDAC4HDAC2HDAC8 | |
| SCHEMBL4623136 | 0.88 | PDCD1 (0.40) | PDCD1CD274HDAC4HDAC2HDAC8 | |
| SCHEMBL5689152 | 0.87 | EDNRB (0.35) | PDCD1CD274TP53L3MBTL1NPC1 | |
| SCHEMBL5689647 | 0.83 | PDCD1 (0.35) | PDCD1CD274HDAC4HDAC2HDAC8 | |
| SCHEMBL5691597 | 0.83 | TSHR (0.35) | TP53L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL5691739 | 0.82 | HEXA (0.38) | TP53HEXAHEXBMAPT | |
| SCHEMBL5689656 | 0.80 | KDM4E (0.38) | TP53L3MBTL1DHFRMAPTSMN1; SMN2 | |
| SCHEMBL5691202 | 0.79 | RXRA (0.33) | L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL28755431 | 0.79 | PPARG (0.34) | — | |
| SCHEMBL5600529 | 0.79 | PDCD1 (0.39) | PDCD1CD274HDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511755-B1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050182266-A1 | Transition metal componds their preparation and their use in catalyst systems for the polymerization and copolymerization of olefins | BASELL POLYOLEFINE GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1511755-A1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | Basell Polyolefine GmbH (DE) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106470-A1 | TRANSITION METAL COMPOUNDS THEIR PREPARATION AND THEIR USE IN CATALYST SYSTEMS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182266-A1 | Transition metal componds their preparation and their use in catalyst systems for the polymerization and copolymerization of olefins | YAP1, COX14, CYCS | PDCD1 536/4885CD274 1752/4885HDAC4 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.